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ABSTRACT
Medulloblastoma (MB) is the most common malignant brain tumor in children. 
Despite therapeutic advancements, high-risk groups still present significant mortality. 
A deeper knowledge of the signaling pathways contributing to MB formation and 
aggressiveness would help develop new successful therapies. The target of rapamycin, 
mTOR signaling, is known to be involved in MB and is already targetable in the clinical 
setting. Furthermore, mTOR is a master metabolic regulator able to control cell 
growth versus autophagy decisions in conditions of amino-acid deprivation that can 
be due to IDO1 enzymatic activity. IDO1 has been also implicated in the regulation 
of inflammation, as well as of T cell-mediated immune responses, in a variety of 
pathological conditions, including brain tumors. In particular, IDO1 induces expansion 
of regulatory T-cells (Treg), preventing immune response against tumor cells. Analysis 
of 27 MB tissue specimens for the expression of both mTOR and IDO1 showed their 
widespread expression in all samples. Testing their cooperation in vitro, a significant 
involvement of IDO1 in mTOR immunogenic pathway was found, able to counteract 
the aim of rapamycin treatment. In MB cell lines, inhibition of mTOR strongly induced 
IDO1 expression and activity, corroborating its ability to recruit Treg cells in the tumor 
microenvironment. The mTOR/IDO1 cross talk was found to be strictly specific of MB 
cells. We demonstrated that mTOR pathway cross talks with IDO1 pathway to promote 
MB immune escape, possibly contributing to failure of mTOR- targeted therapy. 
INTRODUCTION
Medulloblastoma (MB) is the most common 
malignant brain tumor in children, with several pathways 
implicated in its development [1, 2]. MB belongs to the 
embryonic tumor family and recent genomic studies 
have led to a novel classification into four molecular 
subgroups (i.e. WNT; Sonic Hedgehog Homolog, SHH; 
Group 3 and Group 4). WNT and SHH groups are 
characterized by activation of WNT/beta-catenin and SHH 
pathway, respectively. Group 3 and 4 are less genetically 
characterized, the first predominantly showing C-MYC 
amplification while Group 4 is often characterized by 
MYCN amplification and presence of iso-chromosome 
17q [3, 4]. Current treatments can cure about 80% of 
MB patients, however at the cost of significant long-term 
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toxicities [5]. Preclinical studies have revealed the potential 
of molecular targeted therapy in treating MBs [6]. The 
PI3K/Akt/mTOR pathway is a key player in many types 
of cancer and its pharmacological targeting via molecular 
inhibitors is proving to be promising in MB as well [7]. 
In particular, mTOR is a member of the PI-3 kinase-like 
kinase family (PIKKs), which plays an integral role in 
coordinating cell growth and division in response to growth 
factors, nutrients and energy status of the cell [8]. Upon 
activation, mTOR is phosphorylated on several residues, 
and such phosphorilated form (P-mTOR) is involved in 
development and progression of MB [9, 10]. Indeed, a 
recent study in 40 primary MB specimens suggested a 
possible synergistic effect between mTOR inhibitors and 
conventional chemotherapy in MB with activated mTOR 
pathway [11]. Furthermore, mTOR is a master metabolic 
regulator, with a key role as a nutrient sensor being able 
to control cell growth versus autophagy decisions in 
conditions of amino acid deprivation [12]. In particular, 
Tryptophan (TRP) depletion is governed by indoleamine 
2,3-dioxygenase (IDO1), which catalyzes the first rate-
limiting step in the consumption of TRP [13]. Such IDO1-
mediated TRP depletion from tissues alters inflammation, 
as well as T-cell mediated immune response, in a variety of 
pathological settings, including cancer and, in particular, 
brain tumors [14]. Interferon gamma (IFNγ), a potent IDO1 
inducer, depletes TRP and represses mTOR activity in Hela 
cells [15]. In glioblastoma, the IDO1-mediated response 
depends on the increase of chemokines like CCL2, able to 
attract Tregs [16]. More in general, IDO1-mediated TRP 
depletion establishes an immunosuppressive environment, 
amplifying tolerogenic antigen-presenting cells (APC), 
expanding Treg and downregulating cytotoxic T-cell 
activity, thus preventing immune response to tumor cells 
[17]. Based on this body of evidence, the aim of our study 
was to evaluate the IDO1/mTOR pathway crosstalk in MB 
and its role in immune escape. 
RESULTS
mTOR and IDO1 are co-expressed in MB tissue 
samples
Histological analysis in our population of 27 MB 
patients showed 15 classic, 7 desmoplastic and 5 anaplastic 
forms. Based on age the patients were divided in infants 
(6 children under age of 3) and child (21 patients). We 
found a predominance of molecular subgroups 3 and 4 in 
our series; WNT = 6, SHH = 5, group 3 = 9 and group 
4 = 7 patients (Table 1).
Immunohistochemistry (IHC) analysis on surgical 
samples revealed that all were positive for mTOR and 
IDO1 and that 85% expressed P-mTOR, compared with 
negative controls (Figure 1A, Table 1), irrespective of 
molecular subgroup. Similarly, looking at IDO1 mRNA 
expression in available microarray datasets (R2 and 
Oncomine) we did not find changes across MB subgroups 
(Supplementary Figure 1). Western blot analysis confirmed 
the expression pattern, documenting the presence of IDO1 
in MB tissue (Figure 1B).
mTOR inhibition induces IDO1 expression in 
MB cell line
In DAOY cells, IDO1 was expressed only after 
IFNγ stimulation. In particular, IDO1 was induced 6 hours 
after IFNγ treatment, while IDO1 enzymatic activity, 
measured as the amount of the metabolite kynurenine 
detectable in the supernatant, started after 16 hours (Figure 
2A, 2B). IDO1 enzymatic activity reached its peak after 
48 hours and correlated with the highest levels of mTOR 
phosphorylation status, suggesting a functional correlation 
between them. To better understand mTOR-signaling-
dependent modulation of IDO1 expression and function, 
we added the mTOR inhibitor rapamycin to DAOY cells 
followed by IFNγ stimulation. Unexpectedly, we observed 
that P-mTOR downregulation strongly enhanced the 
IFNγ-dependent IDO1 expression compared to control 
samples (Figure 2C, 2D). Furthermore, induction of IFNγ-
dependent IDO1 expression by rapamycin treatment was 
so effective to revert IDO1 interference when compared 
with that induced by IFNγ alone (Figure 2C, 2D). 
Altogether, these findings suggest a crosstalk between 
the two molecules, and that downregulation of mTOR 
strongly contributes to IFNγ-mediated IDO1 protein 
overexpression. In addition, IDO1 interference negatively 
affected mTOR phosphorylation, suggesting a functional 
loop deserving further investigation.
Rapamycin-dependent IDO1 expression induces 
Treg expansion
IDO1 contributes to the immune escape mechanism 
inducing the expansion of Treg cells through its catabolites 
kynurenines, that are detectable in the culture supernatants 
(SVN) as shown in Figure 3A. For this reason, we 
evaluated the effect of mTOR inhibition on IDO1 
immunosuppressive activity by analyzing the expansion 
of Treg cells, identified by the concomitant CD4/CD25/
FOXP3+ expression on peripheral lymphocyte population. 
CD3+ cells were magnetically sorted from peripheral 
blood of a healthy donor and cultured for 5 days in SVN 
from primary MB cell cultures grown under different 
conditions. In Figure 3B and 3C, we show that the SVN 
obtained from MB cells stimulated with IFNγ was able 
to expand Treg cells population more effectively when 
compared to untreated sample. This was due to the 
kynurenine released into the SVN by IDO1 induction 
as previously demonstrated [18] (Figure 3A). SVN 
obtained from MB cells treated with rapamycin favored 
upregulation of FoxP3 expression [19]. In particular, we 
observed a 22.8% of Treg cells with rapamycin-MB-SVN 
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and even a higher amount or Treg cells reaching 29% 
when SVN obtained from MB cells treated with rapamycin 
and IFNy was employed, this latter value doubling the 
one observed with IFNy alone (Figure 3B). This finding 
suggests that IDO1 expression and activity induced by 
rapamycin constitute a stronger IDO1-dependent immune 
escape mechanism. A possible mediator of IDO1-
dependent Treg expansion is the increase of chemokines 
like CCL2 which attracts Treg cells, leading to a global 
tumor immune tolerance [16, 20]. Thus, we evaluated the 
level of CCL2 expression in MB tissue samples by IHC 
compared with negative control (Figure 3D). As shown 
in Table 2, the totality of samples were highly positive for 
the expression of CCL2, supporting our hypothesis that 
IDO1 expression, by recruiting Treg cells, could create an 
immune-tolerance microenvironment. Such mechanism 
could be responsible for failure of mTOR therapy in MB. 
mTOR-IDO1 interaction is context-dependent in 
brain tumors
To verify whether this peculiar crosstalk between 
mTOR and IDO1 observed in DAOY cells could 
be extended also to other high-grade or low-grade 
brain tumors, we evaluated the expression of the two 
molecules by WB on 4 glioblastoma and 2 ganglioglioma 
tissue specimens. All samples were positive for IDO1, 
p-mTOR and mTOR (Figure 4A). Afterwards, we used 
Figure 1: (A) Representative IHC staining of human MB samples of (a) mTOR 20X, (b) P-mTOR 20X and (c) IDO1 40X 
and negative control for each antibody (CTRL) Scale bar 100 µm. (B) Representative WB analysis performed on MB tissue samples 
for the expression of P-mTOR, mTOR and IDO1. GAPDH Ab expression was used as loading control.
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the glioblastoma cell line KNS-42 and a primary cell 
line obtained from a ganglioglioma tissue sample (#6). 
As shown in Figure 4B, IFNγ-mediated induction of 
IDO1 was strongly reduced by mTOR inhibition with 
rapamycin suggesting that functional relationship 
between mTOR and IDO1 might be specific of MB 
among CNS tumors.
DISCUSSION
Recent advances in identifying molecular pathways 
that enhance amino acid catabolism and downstream 
mechanisms that affect immune cells response support 
the notion that it can regulate innate and adaptive immune 
cells in pathological settings. Limited access to amino 
acids during immune cell activation may compromise 
immune responses by inhibiting immune cell division, 
differentiation, maturation, migration, and acquisition of 
new effector functions [12]. In particular, TRP catabolism 
has emerged as a powerful mechanism of peripheral 
immune tolerance, contributing to maintain homeostasis 
by preventing autoimmunity or immunopathology that 
would result from uncontrolled and overacting immune 
response. IDO1 is one of three enzymes able to catalyze 
TRP degradation along the kynurenine pathway [21]. As 
a result, TRP is locally depleted while TRP catabolites, 
including kynurenine and its derivatives, accumulate. 
Tumors divert the immunosuppressive IDO1 function 
to their own benefit in their continue efforts to resist 
immune aggression [22]. A number of human tumors 
are known to express IDO1 in a constitutive manner and 
most start expressing IDO1 when exposed to IFNγ [14]. 
Ectopic expression of IFNγ during CNS development 
in mice results in cerebellar tumors that share the major 
Table 1: Clinical and pathological characteristics of patients
Patients Age Histopathology mTOR P-mTOR IDO1 Mol. subgroup
#1 Child Anaplastic 3+ 2+ 3+ 3
#2 Child Classic 3+ 2+ 2+ 4
#3 Child Desmoplastic 3+ 2+ 2+ SHH
#4 Child Classic 3+ 1+ 3+ WNT
#5 Child Classic 3+ 1+ 1+ 4
#6 Infant Classic 3+ 0 2+ WNT
#7 Infant Classic 1 + 1+ 1+ 3
#8 Child Classic 2+ 1+ 2+ SHH
#9 Child Desmoplastic 1 + 0 2+ 4
#10 Child Classic 2+ 1+ 3+ 4
#11 Child Anaplastic 3+ 1+ 3+ 3
#12 Child Classic 2+ 1+ 3+ WNT
#13 Infant Anaplastic 3+ 0 3+ 3
#14 Child Anaplastic 2+ 1+ 3+ 3
#15 Infant Desmoplastic 2+ 1+ 3+ SHH
#16 Child Classic 2+ 2+ 1+ 3
#17 Child Desmoplastic 3+ 1+ 1+ SHH
#18 Child Classic 3+ 2+ 2+ 4
#19 Child Classic 3+ 1+ 2+ WNT
#20 Infant Desmoplastic 3+ 1+ 1+ SHH
#21 Child Anaplastic 3+ 2+ 2+ 3
#22 Child Desmoplastic 3+ 2+ 1+ 4
#23 Child Classic 2+ 1+ 1+ 4
#24 Child Classic 2+ 1+ 2+ WNT
#25 Child Classic 3+ 1+ 3+ WNT
#26 Infant Classic 3+ 0 2+ 3
#27 Child Desmoplastic 3+ 2+ 3+ 3
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Figure 2: (A) IFNγ stimulation of DAOY cell line at subsequent time points. P-mTOR, mTOR and IDO1 expression was evaluated 
by WB analysis and compared with kynurenine release in the culture supernatants. HSP70 Ab was used as loading control. (B) Graphic 
representation of densitometric analysis of three independent experiments. P-mTOR was normalized based on the values of mTOR 
expression (left), IDO1 on HSP-70 expression (right) (**P  ≤ 0.01). (C) Rapamycin treatment of DAOY cell line in combination with IFNγ 
stimulation upon IDO1 interference. P-mTOR, mTOR and IDO1 modulations were analyzed by WB. Tubulin Ab was used as loading control. 
(D) Graphic representation of densitometric analysis of three independent experiments. P-mTOR was normalized based on the values of 
mTOR expression (left), IDO1 on tubulin expression (right) (*P  ≤ 0.05). Densitometry was performed with Image J program. 
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molecular and pathological characteristics of human MB 
[23]. Among cell signaling pathways possibly affected 
by IDO1, mTOR has a key role due to its capacity of 
being a nutrient sensor influenced by amino acid levels 
[17]. It has been demonstrated that TRP deprivation 
triggers autophagy in an mTOR-dependent manner and 
induction of autophagy is reversed by restoring essential 
amino acids like TRP. In addition, mTOR acts as a pivotal 
immune modulator playing a crucial role in antigen 
responsiveness in CD4+ cells [24]. This effect seems 
to be mediated by an influence of mTOR inhibition on 
naturally occurring regulatory Treg cells, which have 
a role in immunological tolerance. MB formation and 
growth has been associated with multiple molecular 
aberrations, including those of the mTOR pathway [25]. 
Our findings showed that 100% of MB tissue samples 
are positive for mTOR and IDO1, and that 85% of them 
express P-mTOR. In addition, we found their expression 
to be independent from MB molecular subgroup. However 
such lack of correlation of IDO1 expression with the 
molecular subgroups could be due to the few number of 
MB analyzed and the lacking of available data-set analysis 
on protein expression in MB. Intriguingly, rapamycin was 
able to induce IDO1 expression, contributing to tumor 
immune escape mechanism. Since IDO1 interference 
affected mTOR phosphorylation, we propose IDO1 as 
a possible molecular target in MB. Indeed, this IDO1-
centered concept is supported by numerous preclinical 
studies in models of tumor immunity [26]. Furthermore, 
it is known that prolonged administration of an mTOR 
inhibitor, rapamycin, results in a pronounced increase in 
number of Treg [27]. Given the critical role of Treg cells 
in immune tolerance, it is important to delineate signaling 
pathways that either positively or negatively regulate their 
Table 2: CCL2 IHC analysis
Patients CCL2
#1 2+
#2 2+
#3 3+
#4 2+
#5 3+
#6 3+
#7 2+
#8 2+
#9 1+
#10 2+
#11 2+
#12 1+
#13 2+
#14 2+
#15 2+
#16 3+
#17 1+
#18 2+
#19 3+
#20 2+
#21 3+
#22 2+
#23 2+
#24 3+
#25 2+
#26 2+
#27 3+
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differentiation. The mechanism by which mTOR inhibition 
enhanced FoxP3 expression has not been clarified yet, 
but it is known that mTOR could act directly on signal 
transducer and activator of transcription (STAT3), 
known to be involved in FoxP3 increased transcription 
[28, 29]. Since we previously demonstrated that IDO1 
induction is dependent by STAT3 phosphorylation 
[24], we hypothesize that IDO1 be a possible candidate 
Figure 3: (A) Evaluation of kynurenines released in the supernatants of primary cell lines obtained from three different MB 
tissue samples, in the specific culture conditions. Bars are representative of mean values and standard deviation recorded in three 
independent experiments (*P  ≤ 0.05). (B) Representative CD4/CD25/FoxP3 staining in CD3+ cells stimulated with supernatant obtained 
from specific cultures (1–4) of primary MB cell line (Patient #19), to evaluate the percentage of induced Treg cells. The percentage of 
cells staining positively is indicated. (C) Graphic representation of CD25/FoxP3+ cells fold of induction produced by three independent 
experiment (*P  ≤ 0.05). (D) Representative CCL2 chemokine IHC staining (20×) of human MB samples compared with negative control 
(#19) Scale bar 100 µm.
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for mTOR-dependent Treg expansion. Indeed, in a 
primary MB cell line, we demonstrated that induction 
of IDO1 after rapamycin treatment strongly promote the 
recruitment of Treg cells. This hypothesis is supported 
by the high expression of the Treg attractive chemokine, 
CCL2, observed by IHC in all human MB samples. Since 
IDO1 inhibitors are now being developed clinically for 
the treatment of several cancers with the aim of reversing 
cancer-associated immune suppression [30], we speculate 
that a possible targeting of IDO1 in MB could improve 
tumor eradication by acting at different levels. Indeed, 
IDO1 down-regulation can impair both mTOR activation 
and Treg-dependent tumor immune escape mechanism. 
Furthermore, we found this effect to be specific for MB, 
since it was not found in different brain tumors and we 
provide evidence of molecular crosstalk between mTOR 
and IDO1. The unexpected Treg-mediated immune-escape 
response induced by rapamycin treatment suggests caution 
in using mTOR inhibitors in MB, at least as single agent 
therapy. Advancements in molecular profiling might allow 
implementation of MB subgrouping with IDO1 activation 
profiling, indicating possible benefit from molecularly 
driven combinatorial approaches, including IDO1 targeted 
therapy.
Figure 4: (A) Analysis of P-mTOR, mTOR and IDO1 in 4 Glioblastoma tissue samples (left panel), and 2 Ganglioglioma 
samples (right panel) by WB. GAPDH was used as loading control. (B) Rapamycin treatment in combination with IFNγ stimulation in 
KNS-42 cell line (left panel) and Ganglioglioma primary cell line from patient #6 (right panel). P-mTOR, mTOR and IDO1 modulation was 
analyzed by WB. GAPDH Ab was used as loading control. IDO1 expression was correlated with kynurenine release in culture supernatants. 
Similar results were obtained in 3 independent experiments.
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MATERIALS AND METHODS
Human tissue samples
Formalin-fixed, paraffin-embedded samples 
of primary MB from 27 consecutive patients treated 
at Bambino Gesù Children’s Hospital between 2013 
and 2015 were examined. A part of every sample was 
cryopreserved for protein extraction at time of surgery. 
MB diagnosis was made complying with WHO 2007 
criteria. The study was approved by the Institutional 
Review Board. MB molecular subgroup was determined 
by qRT-PCR as previously described [31, 32].
Gene expression data set analyses
The Oncomine platform (https://www.oncomine.
org/resource/login.html) and R2: Genomics Analysis and 
Visualization Platform (http://r2.amc.nl) were used to 
interrogate all data sets. Two data sets in R2 ([33], RNA) 
and [34] DNA) and Three in Oncomine ([20] RNA and 
[35], for both RNA and DNA) were interrogated to assess 
IDO1 levels across MB subgroups. 
Immunohistochemistry
Three mmm paraffin-embedded sections were 
dehydrated, pretreated with avidin block for 15 min 
and biotin block for 15 min, then incubated with bovine 
serum albumin (BSA) for 30 min and overnight at 
4°C with monoclonal rabbit antibodies against mTOR 
(Cell Signaling Technology, 1:50 dilution, PT-link pre-
treatment at high pH) and Phospho-mTOR (Cell Signaling 
Technology, 1:100 dilution, PT-link antigen retrieval 
at high pH). Incubation with biotinylated secondary 
antibodies for 15 min at room temperature and incubation 
with alkaline phosphatase conjugated streptavidin for 15 
min at room temperature were performed. Other 3 mmm 
paraffin embedded sections were incubated with primary 
antibodies against IDO1 (Santa Cruz Biotechnology, 
rat monoclonal Ab, 1:250) for 60 min at 37°C and then 
with secondary antibodies (polyclonal rabbit anti-
rat biotynilated Igs Dako, 1:200) for 30 min at 37°C. 
Chromogenic development was obtained using Fast 
Red (Dako Real kit). Other 3 mmm paraffin-embedded 
sections were incubated with primary antibodies against 
CCL2 (R&D Systems, monoclonal mouse, 1:25 dilution, 
PT-link antigen retrieval at high pH) over night at 4°C 
and then with Flex HRP (enzyme horseradish peroxidase, 
Dako) for 20 min at room temperature. Chromogenic 
development was obtained using 3,3′-diaminobenzidine 
tetrahydrochloride with 0.03% hydrogen peroxidase 
(Dako). Finally, all sections were counterstained with 
haematoxylin, cleared and mounted. Sections were 
visualized with a Zeiss AXIO microscope and digital 
image acquisition performed with attached Zeiss AxioCam 
MRc5 using the AxioVision 4.8 software.
Cell cultures and treatments
Daoy MB cell line was purchased from 
ATCC (HTB-186) and maintained in RPMI medium 
supplemented with 10% fetal calf serum (FCS) (Gibco), 
L-glutamine and penicillin/streptomycin (Euroclone) 
at 37°C in humidified 5% CO2 air. KNS-42 high-grade 
glioma cell line was obtained from Japan Health Sciences 
Foundation, Health Science Research Resources Bank and 
grown in DMEM/F12 medium + 10% FCS at 5% CO2, as 
previously described [36]. MB and ganglioglioma primary 
cell lines were obtained from fresh tissue samples and 
maintained in culture with RPMI supplemented with 20% 
FCS. After 1 week, the supernatant was removed from 
cultures and replaced with fresh medium. Two weeks from 
the start of the culture, cells were harvested and replated 
to perform the experiments. In order to study IDO1/
mTOR crosstalk, cells were plated at 1.6 × 105 cells/well 
in 6-wells plates. On day two, medium was replaced with 
a serum-free one for rapamycin (Cell Signaling) addition 
(10 mM) and maintained overnight. On day three, IFNγ 
(Immunological Sciences) was added at 100 ng/ml fresh 
medium for 16 hours. At the end of treatment, supernatant 
was collected for the quantification of kynurenine 
production and the cells were lysed for protein extraction.
IDO1 interference
Daoy cells were plated at 1.6 × 105 cells/well 
in 6-wells plates. The day after, cells were transiently 
transfected by Lipofectamine 2000 (ThermoFisher) 
with control shRNA or IDO shRNA plasmid (Santa 
Cruz Biotechnology) following the manufacturer’s 
protocol. Twenty four hours after transfection cells were 
stimulated with IFNγ for 16 hours. At the end of treatment, 
supernatants were collected for the quantification of 
kynurenine production and cells were lysed for protein 
extraction.
Western blotting
At the end of treatments, cell pellets were lysed 
with RIPA buffer [150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris–HCl 
(pH = 8), 1 mM PMSF, 1 mM EGTA, 50 mM NaF, 50 mM 
Na3VO4 and protease inhibitors (Roche, Milan, Italy)]. 
Cell lysates were incubated on ice for 20 minutes and 
clarified by centrifugation at 14,000 rpm for 20 minutes. 
Cell extracts obtained with RIPA buffer were boiled 
for 5 minutes at 95°C and analyzed by SDS-PAGE. 
Samples were transferred onto nitrocellulose membrane 
(Bio- Rad, Milan, Italy). Blots were probed with primary 
antibodies (anti-P-mTOR, mTOR, IDO1, GAPDH from 
Cell Signaling; anti-actin and anti-tubulin from Santa 
Cruz Biotechnologies) washed and developed with 
HRP- conjugated rabbit or mouse secondary antibodies 
(Cell Signaling), as appropriate. 
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IDO1 activity
TRP and kynurenine levels were measured with 
reverse-phase HPLC Agilent Technologies 1200. 
Briefly, sample aliquots (200 μL) were diluted with 
200 μL potassium phosphate buffer (0.05 mol/L pH 6.0) 
containing the internal standard 3-nitro-L-tyrosine 
(100 mmol/L). Proteins were precipitated with 50 μL 
of trichloroacetic acid (2 mol/L). Capped tubes with 
the precipitate were immediately vortex-mixed and 
centrifuged for 10 min at 13,000 g. One-hundred-fifty 
microliters of supernatant was transferred into microvials 
and placed in the autosampling device. Samples were 
analyzed using a Protecol C18HPH 150 × 4.6 mm 5 μ 
column (SGE Analytical Science), a double-pump 
HPLC apparatus (Agilent Technologies) equipped with 
spectrophotometric and fluorescence detectors. TRP 
was detected by a fluorescence detector at an excitation 
wavelength of 285 nm and an emission wavelength of 
365 nm. Kynurenine and nitrotyrosine were detected by 
recording UV absorbance at a wavelength of 360 nm. 
Elution solvent was as follows: buffer A: potassium 
phosphate solution (0.015 mol/L, pH 6.4) containing 
27 mL acetonitrile. Buffer B: acetonitrile. Analysis was 
carried out at a flow rate of 1 mL/min at 25°C for 12 min. 
Concentration of components was calculated according 
to peak heights and was compared with both 3-nitro-
L-tyrosine as internal standard and reference curves 
constructed with L-tryptophan (concentration 10 ,20, 
30 mmoli/L) and KYN (10, 20, 30 mmoli/L). The intra-
daily coefficient of variation was 1.20% for TRP and 
1.25% for kynurenine. Inter-days coefficient was 3.5% for 
TRP and 3.8% for kynurenine.
Mixed tumor-cell lymphocyte cultures (MTLC)
CD3+ cells were positively selected from buffy-
coat preparations of volunteer blood donors with directly 
conjugated anti-CD3 magnetic microbeads (Miltenji). 
CD3+cells were plated on 96-well plates at 2 × 105 cells/
well in the supernatants obtained by MB primary cell line 
(#19) culture conditions. After 5 days, cells were harvested 
to evaluate Treg expansion. IL-2 (Immunological Science) 
was added to the MTLC at 10 IU/ml.
FACS analysis
Treg expansion was evaluated following the 
manufacturer’s protocol (BD Pharmingen). Briefy CD3+ 
cells, cultured in Daoy supernatants, were harvested 
and washed with PBS 1% BSA and stained for APC-
conjugated anti CD4 and PE-conjugated and CD25 
antibody for 15 minutes. Cells were then washed and 
re-suspended in fixation buffer for 10 minutes. Upon 
centrifugation, supernatant was discarded and cells were 
re-suspended in permeabilization buffer for 30 minutes. 
Upon washing of the cells, samples were stained with 
FITC-conjugated anti FoxP3 antibody for 30 minutes. At 
the end of the staining process, samples were washed and 
re-suspended in PBS for FACS analysis (FACS CANTO 
II, BD).
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